NCT06864403View on ClinicalTrials.gov

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

PHASE4RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
PouchitisPouches, IleoanalPouch, Ileal
Interventions
DRUG

Mirikizumab - Intravenous (IV)

300 mg mirikizumab at Weeks 0, 4, and 8

DRUG

Mirikizumab - Subcutaneous (SC)

Pre-filled syringes administered at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

Trial Locations (4)

10016

RECRUITING

NYU Langone Health, New York

15212

NOT_YET_RECRUITING

Allegheny Health Network, Pittsburgh

55905

RECRUITING

Mayo Clinic, Rochester

27599-7080

RECRUITING

University of North Carolina, Chapel Hill

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER